FDA 483 - Gemini Pharmaceuticals, Inc. - July 26, 2022

An FDA inspection of Gemini Pharmaceuticals, Inc. in Commack, NY, revealed a significant deficiency in their manufacturing processes. The firm failed to verify that finished batches of dietary supplements met product specifications for identity, purity, strength, and composition. This was specifically noted by the absence of finished product testing for several dietary supplement products.